Sugi Predict

Sugi Predict / Compounds / SCHEMBL1448375

SCHEMBL1448375

SCHEMBL1448375

COC(=O)c1c([N+](=O)[O-])ccc(OC)c1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.49
▸ ALDH1A1 P00352 8/20 0.49
▸ KMT2A Q03164 7/20 0.48
▸ MAPT P10636 6/20 0.48
▸ MEN1 O00255 5/20 0.48
▸ TDP1 Q9NUW8 4/20 0.46
▸ KDM4E B2RXH2 3/20 0.46
▸ POLB P06746 3/20 0.46
▸ CTDSP1 Q9GZU7 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ CYP3A4 P08684 2/20 0.46
▸ TSHR P16473 2/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ HTT P42858 1/20 0.45
▸ ALOX12 P18054 2/20 0.44
▸ ABCC4 O15439 1/20 0.44
▸ PLIN1 O60240 1/20 0.44
▸ CACNA1F O60840 1/20 0.44
▸ GMNN O75496 1/20 0.44
▸ KCNK2 O95069 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13520113 0.88 TDP1 (0.50) LMNAALDH1A1KMT2AMAPTMEN1
SCHEMBL31305226 0.88 TDP1 (0.50) LMNAALDH1A1KMT2AMAPTMEN1
SCHEMBL31146147 0.86 TDP1 (0.53) ALDH1A1KMT2AMAPTMEN1TDP1
SCHEMBL1448299 0.86 TDP1 (0.53) ALDH1A1KMT2AMAPTMEN1TDP1
SCHEMBL31146138 0.86 TDP1 (0.53) ALDH1A1KMT2AMAPTMEN1TDP1
SCHEMBL27474575 0.84 TDP1 (0.46) LMNAALDH1A1KMT2AMAPTMEN1
SCHEMBL27248642 0.83 LMNA (0.48) LMNAALDH1A1KMT2AMAPTMEN1
SCHEMBL6902580 0.83 KMT2A (0.58) LMNAALDH1A1KMT2AMAPTMEN1
SCHEMBL1448339 0.83 CA12 (0.46) LMNAALDH1A1KMT2AMAPTMEN1
SCHEMBL30954151 0.81 TDP1 (0.50) LMNAALDH1A1KMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360085-A1 Glucose Uptake Inhibitors KADMON CORPORATION, LLC (US) 2024-10-31 — — US disclosed
US-12060347-B2 Bicyclic heteroaryl substituted compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-13 — — US disclosed
US-12030857-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2024-07-09 — — US disclosed
US-12030857-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2024-07-09 — — US disclosed
CN-109689647-B Bicyclic heteroaryl substituted compounds 百时美施贵宝公司 2023-01-20 — — CN disclosed
US-20220363648-A1 Glucose Uptake Inhibitors KADMON CORPORATION, LLC 2022-11-17 — — US disclosed
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 — — US disclosed
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 — — US disclosed
EP-3484878-B1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-08-19 — — EP disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 — — US disclosed
EP-1784399-B1 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2011-06-15 — — EP disclosed
US-7910585-B2 Pyrimidine derivatives NOVARTIS AG (CH) 2011-03-22 — — US disclosed
US-7910585-B2 Pyrimidine derivatives NOVARTIS AG (CH) 2011-03-22 — — US disclosed
US-7910585-B2 Pyrimidine derivatives NOVARTIS AG (CH) 2011-03-22 — — US disclosed
WO-2010117425-A1 CERTAIN SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE BIOGEN IDEC MA INC. (US) 2010-10-14 — — WO disclosed
US-20080293708-A1 Pyrimidine Derivatives NOVARTIS AG (CH) 2008-11-27 — — US disclosed
US-20080293708-A1 Pyrimidine Derivatives NOVARTIS AG (CH) 2008-11-27 — — US disclosed
US-20080293708-A1 Pyrimidine Derivatives NOVARTIS AG (CH) 2008-11-27 — — US disclosed
EP-1784399-A2 PYRIMIDINE DERIVATIVES Novartis AG (CH) 2007-05-16 — — EP disclosed
WO-2006021457-A2 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2006-03-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030857-B2 Glucose uptake inhibitors SLC2A1, SLC2A4, SLC2A2 LMNA 4856/4885ALDH1A1 1422/4885KMT2A 1406/4885
US-20220363648-A1 Glucose Uptake Inhibitors SLC2A1, SLC2A4, SLC2A2 LMNA 4856/4885ALDH1A1 1422/4885KMT2A 1406/4885
US-12060347-B2 Bicyclic heteroaryl substituted compounds F2, F2RL3, F12 LMNA 603/4885ALDH1A1 1598/4885KMT2A 2390/4885
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 LMNA 745/4885ALDH1A1 1618/4885KMT2A 2420/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 LMNA 603/4885ALDH1A1 1598/4885KMT2A 2390/4885
US-20080293708-A1 Pyrimidine Derivatives DPYD, TYMP, TYMS LMNA 3279/4885ALDH1A1 955/4885KMT2A 3238/4885
US-20240360085-A1 Glucose Uptake Inhibitors SLC2A3, SLC2A1, SLC2A4 LMNA 4839/4885ALDH1A1 1565/4885KMT2A 1345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.